Private Equity Ownership Tied to Higher Costs to Patients
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
FRIDAY, July 21, 2023 -- Private equity ownership of health care operations is associated with increases in costs to patients and decreases in quality of care, according to a review published online July 19 in The BMJ.
Alexander Borsa, from Columbia University in New York City, and colleagues conducted a systematic literature review to identify studies assessing trends and impacts of private equity ownership of health care operators.
Based on 55 included studies, the researchers found that the United States was the most studied country (47 of 55 studies) and that nursing homes were the most studied setting (17 studies), followed by hospitals and dermatology settings (nine studies each). Consistently, private equity ownership was associated with increases in costs to patients or payers. Impacts on quality were mixed to harmful, with consistent findings in sensitivity analyses limited to studies with a moderate risk for bias. The volume of studies was insufficient to assess impact of private equity ownership on health outcomes and costs to operators. There was an association observed between private equity ownership and reduced nurse staffing levels or a shift toward lower nursing skill mix. There were no consistent beneficial impacts of private equity ownership seen.
"The current body of evidence is robust enough to confirm that private equity ownership is a consequential and increasingly prominent element in health care, warranting surveillance, reporting, and possibly increased regulation," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.